何云东

2009.9-2014.12：华东师范大学，生物医学专业（上海市重点实验室），博士

2003.9-2007.7：  合肥工业大学，生物技术专业，本科

2021.12-至今：  华东师范大学，研究员（上海市重点实验室）

2018.8-2021.8： 美国梅奥医学中心，助理研究员（美国Top1医院）

2015.4-2018.8：美国梅奥医学中心，博士后（美国Top1医院）

2007.9-2008.7： 大学生西部计划志愿服务（支教）

何云东，研究员，博士生导师，华东师范大学“紫江青年学者”。主要从事抗肿瘤新药开发研究和药物耐药分子机制研究。曾获教育部科技进步一等奖、上海市浦江人才、美国“Mayo Edward C. Kendall Fellowship in Biochemistry Award”。目前以第一作者在国际主流期刊包括Signal Transduction and Targeted Therapy（IF: 38.104, SCI1区 ）、Journal of Clinical Investigation（IF: 19.456，SCI1区 ）、Nature Communications（两篇，IF: 17.694，SCI1区 ）、Nucleic Acids Research（IF: 19.16, SCI1区 ）、Clinical Cancer Research（IF: 13.801, SCI1区 ）、 Cancer Research（IF: 13.312, SCI1区）、Oncogene（IF: 9.867, SCI1区）、Frontiers in Oncology（IF: 6.244, SCI2区）、British Journal of Dermatology（IF: 11.113, SCI2区）等发表多篇高质量学术论文，并且以参与作者发表论文在Nature Medicine、EMBO Molecular Medicine、EMBO J、Advanced Science 等，共发表SCI 学术论文30余篇。

受邀为STTT、Mol Cell、Nat Commun、Cancer Res、Cancer Lett、Oncogene等SCI期刊的审稿人

主要从事抗肿瘤新药开发研究和药物耐药分子机制研究，包括：1. 通过构建药物筛选系统，筛选小分子药物并阐明其抗肿瘤功能和分子机制。2.通过RNA-seq 、ChIP-seq、大数据分析、PDX（Patient-Derived Xenografts）、转基因小鼠模型等方法揭示导致前列腺癌抗雄激素治疗抵抗的耐药途径和分子机制。3.通过大规模病人临床数据分析、小鼠肿瘤模型及多种生化分子实验手段阐明前列腺癌对免疫治疗及化疗不敏感的分子机制。

授课包括本科生课程《生物化学》、《微生物学实验》，研究生课程《生物技术与工程》、《生物与医药前沿进展》。

发表论文：

1. Bao X*, Liang Y , Chang H, CaiT, Feng B, Gordon   K, Zhu Y, Shi H, He Y *, Xie L*. Targeting proprotein convertase   subtilisin/kexin type 9 (PCSK9): from bench to bedside. 2024 Jan 8;9(1):13.  Signal Transduction and Targeted Therapy,  2024 Jan 8;9(1):13. IF: 38.104, SCI1区 （共通信作者)

2. He Y, Xu W, Xiao Y, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7(1):198. IF: 38.104, SCI1区 （第一&通信作者) 

3. He Y, Wang L, Wei T, Su H, Hollern D, Ma J, Wen S, Xie H, Yan Y, Pan Y, Tang X, Suman V, Carter J, Weinshilboum R, Wang L, Kalari K, Boughey J, Dong H, Ye D, Perou C, Goetz M, Ren S and Huang H.  FOXA1 overexpression inhibits interferon signaling and immune response in cancer. Journal of Clinical Investigation, 2021. IF: 19.456, SCI1区（第一作者)

4. He Y, Wei T, Lin D, Fazli  L, Karnes R, Jimenez R, Wang L, Wang L, Gleave M, Wang Y and Huang H. A noncanonical  AR addiction drives enzalutamide resistance in prostate cancer. Nature Communications, 2021.  IF: 17.694, SCI1区（第一作者)

5. He Y, Lu J, Ye Z, Hao S,  Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Research, 2018. IF:19.16, SCI1区（第一作者)

6. He Y, Zhao Y, Wang L, Bohrer LR, Pan Y, Wang L, Huang H. LSD1 promotes S-phase entry and  tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. Oncogene, 2017. IF: 9.867, SCI1区（第一作者)

7. He Y, Peng S, Wang J, Chen H, Cong X, Chen A, Hu M, Qin M, Wu H, Gao S, Wang L, Wang X, Yi Z, Liu M. Ailanthone targets p23 to overcome MDV-3100 resistance in castration-resistant prostate cancer. Nature Communications, 2016. IF: 17.694, SCI1区（第一作者)

8. Blee A*, He Y*, Yang Y*, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H. TMPRSS2-ERG  controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer. Clinical Cancer Research, 2018. IF: 13.801, SCI1区(*共同第一作者)

9. Shi L*, Yan Y*, He Y*, Yan B, Pan Y, Orme J, Zhang J, Xu W, Pang J, Huang H. Mutated SPOP E3 ligase promotes 17βHSD4 protein degradation and drives androgenesis and prostate cancer progression. Cancer      Research. 2021., IF: 13.321, SCI1区(*共同第一作者)

10. Cong X*, He Y*, Wu H*, Wang D, Liu Y, Shao T, Liu M, Yi Z, Zheng J, Peng S, Ding T. Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122. Frontiers in Oncology, 2021. IF: 6.244, SCI2区(*共同第一作者)

11. He Y, Liu Y, Lin Q, Zhu J, Zhang Y, Wang L, Ren XL, Ye X. Polydatin suppresses ultraviolet B induced      cyclooxygenase 2 expression in vitro and in vivo via reduced production of reactive oxygen species. British Journal of Dermatology, 2012. IF: 11.113, SCI2区（第一作者)

12. Li G*, He Y*, Zhou W, Wang P, Zhang Y, Tong W, Wu H, Liu M, Ye X, and Chen Y. Identification, synthesis and photo-protection evaluation of aryl thiazole derivatives as a novel series of sunscreens. Heterocycles, 2014. (*共同第一作者)

13. Wen S, He Y, Wang L, Zhang J, Quan C, Niu Y, Huang H. Aberrant activation of super enhancer and choline  metabolism drive antiandrogen therapy resistance in prostate cancer. Oncogene, 2020. IF: 9.867, SCI1区

14. Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, Yan W, Kharbanda A, Li H, Huang H. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O‘PROTAC): Effective Targeting of LEF1 and ERG. Advanced Science, 2021. IF: 17.521, SCI1区

15. Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, Yan Y, He Y, Wang L, Wang Y, Mer G, Ye D, Wang C, Huang H. SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nature Communications, 2021. IF: 17.694, SCI1区

16. Lin Q, He Y, Wang X, Zhang Y, Hu M, Guo W, He Y,  Zhang T, Lai L, Sun Z, Yi Z Liu M, Chen Y. Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression. Advanced Science, 2020. IF: 17.521, SCI1区

17. Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Intrinsic BET      inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET  protein stabilization and AKT-mTORC1 activation. Nature Medicine, 2017. IF: 87.241, SCI1区

18. Peng S, Wang J, Chen H, Hu P, He X, He Y, Wang M, Tang W,  He Q, Wang Y, Xie J, Guo D, Ren S, Liu M, Qiu W, Yi Z. Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain. Cell Biology and Toxicology,2020. IF: 6.691, SCI2区

19. Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. EZH2 cooperates with  gain-of-function      p53 mutants to promote cancer growth and metastasis. EMBO J,  2019. IF: 11.598, SCI1区

20. Wang J, Xing Y, Wang Y, He Y, Wang L, Peng S, Yang L, Xie J, Li X, Qiu W, Yi Z, Liu M. A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer. J Exp Clin Cancer Res, 2019. IF: 11.161, SCI2区

21. Y Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, He Y, Wang D, and Huang H. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Molecular Medicine, 2018. IF: 12.137, SCI1区

22. Yang Y, Bai Y, He Y, Zhao Y, Chen J,  Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W. PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer. Clinical Cancer Research, 2017. IF: 12.531, SCI1区

23. Yang Y, Blee AM, Wang D, An J, Pan Y, Yan Y, Ma T, He Y, Dugdale J, Hou X, Zhang J, Weroha SJ, Zhu WG, Wang YA, DePinho RA, Xu W,  Huang H. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to      Promote Prostate Tumorigenesis and Cell Invasion. Cancer Research, 2017. IF: 12.531, SCI1区

24. Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant  prostate cancer. Oncotarget, 2016. IF: 5.168

25. Li P, Liu Y, Wang H, He Y, Wang X, He Y, Lv F, Chen H, Pang X, Liu M, Shi T, Yi Z. PubAngioGen: a database and  knowledge for angiogenesis and related diseases. Nucleic Acids Research, 2015; 43:D963-7. IF: 16.971, SCI1区

26. Qin M, Peng S, Liu N, Hu M, He Y, Li G, Chen H, He Y, Chen  A, Wang X, Liu M, Chen Y, Yi Z. LG308, a Novel Synthetic Compound with  Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2015. IF: 4.030, SCI2区

27. Hu M, Peng S, He Y, Qin M, Cong X,  Xing Y, Liu M, Yi Z.  Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer. Oncotarget, 2015. IF: 5.168

28. Zhang H, Hu LY, Hu K, He Y, Wang S, Luo JP. Hydrogen sulfide promotes wheat seed germination and alleviate oxidative damage against copper stress. Journal of Integrative Plant Biology, 2008. IF: 7.061, SCI2区

发明专利：

1. Zhengfang Yi*; Shihong Peng; Yundong He; Wenbo Zhou; Yihua Chen; Mingyao Liu*; Cancer treatment method using ailanthone compounds. 2019-09-24 , 美国,  US10420747B2. (授权专利)

2. 易正芳*; 何云东; 王金花; 彭世鸿; 刘明耀*; 臭椿酮在制备治疗前列腺疾病的药物中的应用, 2017-11-24, 中国, CN201410186500.9. (授权专利)

3. Haojie Huang*; Yundong He; Matthew P.  Goetz; FOXA1 is a Biomarker to Predict the Resistance to Immuno- and Chemo-therapy of Cancer, 2020-02-18, 美国, Mayo Clinic Case #: 2020-020. (申请专利)

4. 仇文卫*; 俞利钢; 刘明耀; 易正芳; 何云东; 汪滢滢; 高伟; 丛晓楠; 秦敏; 紫檀芪-3，4二羟基苯丙酸酯及其制备方法和应用, 2015-04-08, 中国, CN201410033213.4. (授权专利)

5. 陈益华*; 叶希韵; 刘明耀; 李国亮; 何云东; 周文波; 一种芳香基噻唑类化合物及其类似物、用途及其制备方法, 2015-02-18, 中国, CN201110415182.5. (授权专利)

6. 叶希韵*; 刘霞; 刘雨婷;何云东; 刘明耀; 虎杖苷在制备防晒化妆品中的应用, 2011-07-20, 中国,      CN201110202868.6. (申请专利)

2022:             “教育部科技进步一等奖”

2022：           “上海市浦江人才”

2022:              "紫江青年学者”

2018-2020： Mayo Edward C. Kendall Award in Biochemistry (22万美元)